EV and MBV-Mediated MSC Differentiation With Reduced Growth Factors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of cultured meat is hindered by the high cost of growth factors, which are essential for muscle differentiation, and there is a need for cost-effective alternatives that allow for the recycling of supplements and efficient differentiation of mesenchymal stromal cells (MSCs) to non-MSC cell fates.
Innovation Solution
The use of extracellular vesicles (EVs) and matrix-bound vesicles (MBVs) derived from non-MSC sources or differentiated MSCs to induce differentiation, reducing the reliance on growth factors and enabling the production of artificial tissue with multiple cell types in a single vessel.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If growth factors are used to promote muscle differentiation, then differentiation efficiency is improved, but production cost increases significantly
Solution Approach 1:
The patent uses extracellular vesicles (EVs) as an intermediary substance to mediate the differentiation process. Instead of directly applying expensive growth factors to MSCs, the EVs (which contain growth factors and other bioactive molecules) serve as a carrier and mediator, transferring the differentiation signal from donor cells to target MSCs. This intermediary approach maintains differentiation efficiency while reducing direct dependency on expensive growth factor supplements in the culture media.
Solution Approach 2:
The patent employs a copying mechanism where differentiated cells (or EVs derived from them) create copies of the differentiation signal. By harvesting EVs from cells that have already been differentiated using growth factors, and then using these EVs to differentiate additional MSCs, the system creates a reusable copy of the differentiation signal. This allows the expensive growth factor effect to be replicated and reused multiple times without requiring continuous addition of fresh growth factors to each culture.
2Manufacturing precision
If multiple cell types are produced in separate vessels, then cell differentiation control is improved, but device complexity and production scalability worsen
Solution Approach 1:
The patent implements universality by creating a single culture system that can produce multiple different cell types simultaneously. By using different sources of extracellular vesicles (e.g., EVs from adipocytes for adipogenic differentiation, EVs from myotubes for myogenic differentiation) and adding them to the same MSC culture, the system achieves multi-functionality. One culture vessel can thus serve multiple purposes: generating muscle cells, fat cells, or other cell types depending on which EV source is used, eliminating the need for separate dedicated vessels for each cell type.
Solution Approach 2:
The patent applies segmentation by separating the differentiation signals into distinct extracellular vesicle populations from different cell sources. Each EV population carries specific differentiation instructions (adipogenic, myogenic, osteogenic, etc.). By segmenting the differentiation control into discrete EV sources rather than requiring separate physical culture systems, the patent enables independent control of each cell type's differentiation pathway while maintaining a unified production platform.
3Quantity of substance
If growth factor concentration is reduced, then production cost decreases, but cell proliferation and differentiation efficiency worsen
Solution Approach 1:
The patent implements self-service by enabling the culture system to generate its own differentiation signals through EV production. Instead of relying on continuous external supplementation with expensive growth factors, the system uses EVs produced by cells within the culture (or co-cultured cells) to autonomously drive the differentiation of MSCs. The EVs act as self-generated signals that replace the need for external growth factor addition, allowing the system to maintain productivity while reducing external input requirements.
Solution Approach 2:
The patent changes the parameter of differentiation signal delivery from direct growth factor addition to indirect EV-mediated delivery. This parameter change involves transitioning from soluble growth factors in the media to vesicle-encapsulated signals. The EVs protect and deliver growth factors and other bioactive molecules in a more efficient, sustained manner, changing the kinetic and concentration parameters of signal delivery. This allows for reduced overall growth factor consumption while maintaining or enhancing differentiation efficiency through more effective localized delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the efficient differentiation of MSCs to non-MSC cell fates, such as muscle cells, while reducing the need for growth factors, thereby facilitating the scalable production of cultured meat with improved cost-effectiveness and tissue complexity.
Implementation Method 1
The use of extracellular vesicles (EVs) and matrix-bound vesicles (MBVs) derived from non-MSC sources or differentiated MSCs to induce differentiation, reducing the reliance on growth factors
Data Source
AI summary
Methods of differentiating a mesenchymal stromal cell (MSC) to a first non-MSC cell fate, the method comprising contacting the MSC with extracellular vesicles (EVs), matrix-bound vesicles (MBVs) or a combination thereof are provided. Methods of producing artificial tissue by culturing MSCs with two sets of vesicles each comprising EVs, MBVs or both that differentiate MSCs to two different non-MSC cell fates, methods of culturing with reduced growth factors and method of differentiating an MSC to a muscle cell fate are also provided.